albumin for transfusion (Albuminar)
Jump to navigation
Jump to search
Introduction
Tradename: Albuminar [pharmacologic agent].
Indications
- volume expansion/hypovolemia*
- to be used after crystalloid therapy has failed. (see SAFE study)
- replacement solution for plasma exchange
- spontaneous bacterial peritonitis[3]
- large volume paracentesis
* of no mortality benefit in septic shock[2]
Dosage
- 500 mL of 5% albumin (25 g) solution IV PRN Packaging:
- human pooled blood fraction
- 50, 250, 500, 1000 mL, (contains 145 meq of NaCl)
Adverse effects
- infrequent (1-10%)
- other[2]
- bleeding due to decreased coagulation factors & decreasedvplatelet aggregation
- allergic reactions
- secondary Creutzfelt Jacob disease (CJD) is possible
More general terms
More specific terms
Additional terms
References
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 613-614
- ↑ 2.0 2.1 2.2 The NNT: Colloid Solutions for Resuscitation in Critically Ill Patients. http://www.thennt.com/nnt/colloids-for-resuscitation-in-critically-ill-patients/
Perel P, Roberts I Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD000567 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21412866
Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med. 2011 Feb;39(2):386-91. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21248514
Caironi P et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014 Mar 18 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24635772 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1305727 - ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.